NICE recommends Teva ’s Cinqaero to treat severe eosinophilic asthma

The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries ’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic asthma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news